The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | ALTA-1L: brigatinib is superior to crizotinib in ALK+ NSCLC
Sanjay Popat, PhD, MBBS, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, provides an update on the results from the ALTA-1L (NCT02737501), a phase III study of brigatinib versus crizotinib in anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Brigatinib had superior results compared to crizotinib with regards to intracranial progression, the overall intracranial progression free survival hazard ratio was 0.27 following brigatinib treatment. Furthermore, when looking at both systemic and intracranial progression, brigatinib was again superior, even in those who had CNS metastasis at baseline. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
